Wisdomtree Investments

This year's Fastest-Growing Companies marks the 19th running of the list.

See our methodology and credits



To qualify, a company-domestic or foreign-must be trading on a major U.S. stock exchange; report data in U.S. dollars; file quarterly reports with the SEC; have a minimum market capitalization of $250 million and a stock price of at least $5 on June 30, 2015; and have been trading continuously since June 30, 2012. Companies must have revenue and net income for the four quarters ended on or before April 30, 2015, of at least $50 million and $10 million, respectively; and have posted an annualized growth in revenue and earnings per share of at least 15% annually over the three years ended on or before April 30, 2015.

Companies that meet these criteria are ranked by revenue growth rate; EPS growth rate; and three-year annualized total return for the period ended June 30, 2015. (To compute the revenue and EPS growth rates, Fortune uses a trailing four quarters log linear least square regression fit.)

The overall rank is based on the sum of the three ranks. Once the 100 companies are identified, they are then re-ranked within the 100, using the three equally weighted variables. If there is a tie, the company with the larger four-quarter revenue receives the higher rank.

Excluded are real estate investment trusts, limited liability companies, limited partnerships, business development companies, closed end investment firms, companies about to be acquired, and companies that lost money in the quarter ended on or before April 30, 2015. In addition, Fortune excludes companies that have announced intentions to restate previously reported financial data, if these errors appear to have a significant impact. Also, Fortune excludes companies that lost money in the quarter ended May 31 or June 30, if the loss represents a deterioration in business conditions. The data are provided by Zacks Investment Research. The data checking process was aided by information provided by S&P Capital IQ, Hoover’s, FactSet Research Systems, and Morningstar Document Research.

—By Scott DeCarlo, Douglas G. Elam, Orlaith Farrell, Vivian Giang, Kathleen Smyth

This year's Fastest-Growing Companies marks the 19th running of the list. In our annual list of public companies with the most stellar three-year profit, revenue, and stock growth, Facebook makes its first appearance.

See our methodology and credits


Sort by:
  1. Rank
  2. Revenues
  3. Profits
  4. Mkt Value
  5. Rev Growth
  6. Total Return
Clear Filters

Filter by

Fastest Growing Stats
Gained in Rank
Dropped in Rank
Clear Filters

Clear Filters

View The Full List

Gilead Sciences

Rima Kulkarni, a research scientist at Gilead, studies resistance to HIV medicines.
Courtesy of Gilead Sciences

Two drugs for hepatitis C, Harvoni and Sovaldi, helped sales top $7 billion during the final quarter of 2014 for this biopharma company.

Company Information

Location Foster City, CA
Industry Pharmaceuticals
Sector Health Care
Fortune 500 Rank 118
Fortune 500 Profile http://fortune.com/fortune500/gilead-sciences-118/
Current Streak 1
Years on List 6
CEO John C. Martin
Website http://www.gilead.com

Revenue, Net Income

$ millions
Revenue Past Four Quarters 27485
Net Income Past Four Quarters 14207

Growth Rates

EPS 3 yr Annual Growth Rate 67%
Rev 3 yr Annual Growth Rate 43%
Total Return 3 yr Annual Rate 66%
Beat S&P 3 yr Total Return?


EPS Growth Rank 32
Revenue Growth Rank 21
Total Return Rank 21
Fortune's Take On Gilead Sciences
  • Why Cancer Biotech Allogene Just Scored an Eye Popping $324 Million IPO
    The blockbuster public offering pegs Allogene's market value at more than $2 billion.
  • The FDA Is Naming and Shaming Companies Accused of Blocking Cheap Generic Drugs
    Celgene and Novartis are among the companies accused of thwarting generic drugs.
  • Goldman Sachs: China Is Beating the U.S. in the Gene Editing Arms Race
    On hot technologies like CRISPR and CAR-T, China has a leg up, Goldman says.
  • Hepatitis C Drugs Can Cost $84,000. This New One May Be Just As Good—But Cost $300
    The new cure could be a boon to poorer nations.
  • Sign In


    Thank you for your interest in licensing Fortune content. Please find information on various licensing contacts below and choose the one that best suits your needs:

    • 1. To license Fortune articles, excerpts, or headlines for republication in various media (including books, eBooks, film, web, newsletters, newspapers, magazines and others), please email syndication@timeinc.com.
    • 2. To license a Fortune cover, order reprint or e-print copies of an article or cover, or license an accolade, please contact PARS International at www.timeincreprints.com.
    • 3. To license text only photocopies of Fortunearticles as print or digital handouts in academic settings, or in academic coursepacks, please contact the Copyright Clearance Center at www.copyright.com